Tier 2 — strong

Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects

Kyoung-Ah Kim, Pil-Whan Park, Hyung-Kee Kim, Jong-Myung Ha, Ji-Young Park
Journal of clinical pharmacology 2005 45(8):941

Bibliography

PubMed
PMID 16027405
DOI
10.1177/0091270005278407
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPlacebo-controlled crossover drug-interaction study
ModelHuman intervention research
SampleHealthy volunteers; sample size not stated in the indexed abstract
InterventionRepeated quercetin followed by rosiglitazone 4 mg
Duration3 weeks per supplementation period
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2005, this source examined safety, interactions and special populations. Design: Placebo-controlled crossover drug-interaction study. Sample/model: Healthy volunteers; sample size not stated in the indexed abstract. The exposure or intervention was Repeated quercetin followed by rosiglitazone 4 mg. Follow-up or treatment period: 3 weeks per supplementation period.

Rosiglitazone exposure and its metabolic ratio were similar with quercetin and placebo.

Dose and sample size need full-method confirmation. A null result for this substrate and schedule does not establish absence of other drug interactions or acute effects.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Rosiglitazone exposure and its metabolic ratio were similar with quercetin and placebo.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Repeated quercetin followed by rosiglitazone 4 mg; 3 weeks per supplementation period.

What this study can and cannot tell us

  • Dose and sample size need full-method confirmation. A null result for this substrate and schedule does not establish absence of other drug interactions or acute effects.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology